Advertisement · 728 × 90

Posts by Myllia Biotechnology

Preview
Myllia Biotechnology Launches Global Virtual Cell Challenge “Echoes of Silenced Genes”

Read the full PR here: www.biospace.com/press-releas...

2 months ago 1 0 0 0
Myllia's Perturbation Prediction Challenge 2026: Echoes of Silenced Genes - Can you predict how CRISPRi perturbations influence the phenotypes of human cells?

Myllia's Perturbation Prediction Challenge 2026: Echoes of Silenced Genes - Can you predict how CRISPRi perturbations influence the phenotypes of human cells?

🚀 Are you ready to push the boundaries of bio AI foundation models? @mylliabio.bsky.social is thrilled to host "Echoes of Silenced Genes" - A Global Community Prediction Competition!

🔗 Learn more here and join the competition:
myllia.com/events/commu...

#AI #BioAI #CRISPR #Perturb2026

2 months ago 3 2 1 0

Kick off 2026 with a deep dive into single-cell science! 🚀

Join FGCZ & BD Biosciences on March 9 in Zurich for the BD Rhapsody™ Science Days.

Featuring:
🔬 Dr. Simone Picelli (IOB, Basel)
🧬 @mylliabio.bsky.social
🩺 Dr. Marc Beyer (DZNE, Bonn)
✨ Dr. Luciano Martelotto (BD)

🔗 tinyurl.com/wbffw5an

2 months ago 1 1 0 0
Dr. Sami Farhi leads the Spatial Technology Platform at the Broad Institute of MIT and Harvard. The platform’s goal is to bring next-generation spatial transcriptomics and proteomics approaches to bear on large-scale biological problems. In his parallel research lab, Sami focuses on continuing technology development and iPS-based screens for understanding psychiatric disease with optical methods. Sami joined the Broad Institute in July 2018 after completing his Ph.D. in chemical biology at Harvard University. He also holds a B.S. in chemical biology from the University of California, Berkeley.

Dr. Sami Farhi leads the Spatial Technology Platform at the Broad Institute of MIT and Harvard. The platform’s goal is to bring next-generation spatial transcriptomics and proteomics approaches to bear on large-scale biological problems. In his parallel research lab, Sami focuses on continuing technology development and iPS-based screens for understanding psychiatric disease with optical methods. Sami joined the Broad Institute in July 2018 after completing his Ph.D. in chemical biology at Harvard University. He also holds a B.S. in chemical biology from the University of California, Berkeley.

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place from March 18–19, 2026, in Vienna, Austria. The early-bird registration is open via the conference website:

www.perturb2026.bio

Meet the Speaker: Sami Farhi

4 months ago 2 0 0 0
Dr. Ci Chu is the Senior Vice President of AI-Enabled Discovery at Xaira Therapeutics, where he leads the team building the massive biological data generation engine fueling Xaira's generative AI models. With over a decade of experience working at the intersection of discovery biology and AI/ML, he has previously led high-impact functional genomics and multi-modal phenotyping teams at insitro, Verily and Google X.

Dr. Ci Chu is the Senior Vice President of AI-Enabled Discovery at Xaira Therapeutics, where he leads the team building the massive biological data generation engine fueling Xaira's generative AI models. With over a decade of experience working at the intersection of discovery biology and AI/ML, he has previously led high-impact functional genomics and multi-modal phenotyping teams at insitro, Verily and Google X.

Are you interested in single-cell genomics, AI-ready perturbation data and virtual cell models? The registration for the "High-Content CRISPR Screening" conference in March 2026 is open via the website:

perturb2026.bio

Meet the Speaker: Ci Chu

4 months ago 2 1 0 0
We’re excited to announce the expansion of Myllia’s global commercial leadership team: Neil Matharoo has joined as VP, Commercial, North America, and Henrik Schmidt has been promoted to VP, Commercial, Europe & APAC. Their expertise strengthens our ability to support partners worldwide as we advance next-generation CRISPR screening technologies! At Myllia Biotechnology, we’ve built a unique, scalable CRISPR screening platform: - Unbiased drug target discovery powered by high-throughput, pooled CRISPR screening - Primary human cell models that translate in vivo, e.g., T helper cells and myeloid cells - Single-cell resolution for deeply resolved functional genomics Get in touch via info@myllia.com and come join the “High-Content CRISPR Screening” conference in March 2026: www.perturb2026.bio #TeamMyllia #CRISPR #FunctionalGenomics #DrugDiscovery

We’re excited to announce the expansion of Myllia’s global commercial leadership team: Neil Matharoo has joined as VP, Commercial, North America, and Henrik Schmidt has been promoted to VP, Commercial, Europe & APAC. Their expertise strengthens our ability to support partners worldwide as we advance next-generation CRISPR screening technologies! At Myllia Biotechnology, we’ve built a unique, scalable CRISPR screening platform: - Unbiased drug target discovery powered by high-throughput, pooled CRISPR screening - Primary human cell models that translate in vivo, e.g., T helper cells and myeloid cells - Single-cell resolution for deeply resolved functional genomics Get in touch via info@myllia.com and come join the “High-Content CRISPR Screening” conference in March 2026: www.perturb2026.bio #TeamMyllia #CRISPR #FunctionalGenomics #DrugDiscovery

We’re excited to announce the expansion of Myllia’s commercial team: Neil Matharoo has joined as VP, Commercial, North America, and Henrik Schmidt has been promoted to VP, Commercial, Europe & APAC. At @mylliabio.bsky.social, we’ve built a unique, scalable CRISPR screening platform!

4 months ago 4 2 0 0
Dr. Thijn Brummelkamp is Director of Research at the Netherlands Cancer Institute with a research interest in the fields of cell biology and cancer biology. Thijn uses genetics in human cells to identify genes important for human disease. During his Ph.D. studies, Thijn developed a system for expressing shRNA molecules, which allowed for long-term gene inhibition. He used this to carry out the first RNA interference-based screen in human cells, revealing the function of the CYLD tumor suppressor gene. His lab also developed haploid human cells as a genetic model system, using this approach to discover host factors for pathogens, such as the cholesterol transporter NPC1 as the long-sought entry receptor for the Ebola virus. More recently, he has applied haploid genetics to uncover missing enzymes and alternative cellular pathways, leading to the discovery of the elusive enzyme crucial for mature actin production, an alternative triglyceride synthesis pathway, and a pathway that explains DNA damage-induced cancer cell death in the absence of p53.

Dr. Thijn Brummelkamp is Director of Research at the Netherlands Cancer Institute with a research interest in the fields of cell biology and cancer biology. Thijn uses genetics in human cells to identify genes important for human disease. During his Ph.D. studies, Thijn developed a system for expressing shRNA molecules, which allowed for long-term gene inhibition. He used this to carry out the first RNA interference-based screen in human cells, revealing the function of the CYLD tumor suppressor gene. His lab also developed haploid human cells as a genetic model system, using this approach to discover host factors for pathogens, such as the cholesterol transporter NPC1 as the long-sought entry receptor for the Ebola virus. More recently, he has applied haploid genetics to uncover missing enzymes and alternative cellular pathways, leading to the discovery of the elusive enzyme crucial for mature actin production, an alternative triglyceride synthesis pathway, and a pathway that explains DNA damage-induced cancer cell death in the absence of p53.

Are you interested in single-cell genomics and drug target discovery? The "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria.

Conference website: perturb2026.bio

Meet the Speaker: @thijnbrummel.bsky.social

4 months ago 3 1 0 0
Advertisement
Dr. Johannes Zuber is a Senior Group Leader at the Research Institute of Molecular Pathology (IMP) and an Adjunct Professor at the Medical University in Vienna. His lab develops and applies inducible loss-of-function genetic tools (iCas9, Tet-shRNAmir, ARTi, AID2), time-resolved transcriptomics, FACS-based and in-vivo screens to characterize regulatory pathways and dependencies in cancer and tumor-associated immune cells. He has been awarded with the German Cancer Prize in 2016 and elected as an EMBO member in 2022.

Dr. Johannes Zuber is a Senior Group Leader at the Research Institute of Molecular Pathology (IMP) and an Adjunct Professor at the Medical University in Vienna. His lab develops and applies inducible loss-of-function genetic tools (iCas9, Tet-shRNAmir, ARTi, AID2), time-resolved transcriptomics, FACS-based and in-vivo screens to characterize regulatory pathways and dependencies in cancer and tumor-associated immune cells. He has been awarded with the German Cancer Prize in 2016 and elected as an EMBO member in 2022.

Are you interested in single-cell genomics and CRISPR applications? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria.

Website: www.perturb2026.bio

Meet the Speaker: @johanneszuber.bsky.social

5 months ago 4 1 0 0
Dr. Prisca Liberali is Full Professor at ETH Zurich (D-BSSE) and Senior Group Leader at the Friedrich Miescher Institute for Biomedical Research (FMI) in Basel. Her laboratory combines high-content imaging, CRISPR-based perturbations, and computational modeling to uncover how single-cell variability drives tissue self-organization and regeneration. By developing quantitative pipelines that integrate genome editing with multiscale microscopy, her group maps genetic interactions and mechanochemical pathways controlling organoid morphogenesis. Liberali’s work bridges molecular systems biology, developmental dynamics, and quantitative imaging, providing mechanistic insights into how collective behaviors emerge from single-cell decisions.

Dr. Prisca Liberali is Full Professor at ETH Zurich (D-BSSE) and Senior Group Leader at the Friedrich Miescher Institute for Biomedical Research (FMI) in Basel. Her laboratory combines high-content imaging, CRISPR-based perturbations, and computational modeling to uncover how single-cell variability drives tissue self-organization and regeneration. By developing quantitative pipelines that integrate genome editing with multiscale microscopy, her group maps genetic interactions and mechanochemical pathways controlling organoid morphogenesis. Liberali’s work bridges molecular systems biology, developmental dynamics, and quantitative imaging, providing mechanistic insights into how collective behaviors emerge from single-cell decisions.

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria.

The registration and abstract submission is now open via the conference website: perturb2026.bio

Meet the Speaker: @priscaliberali.bsky.social

5 months ago 0 0 0 0
Dr. Yusuf Roohani is a Machine Learning Group Leader at the Arc Institute. His research explores how artificial intelligence can guide experimental design in biological discovery, with a particular focus on predictive models of cell state. Recently, he helped design the Virtual Cell Challenge, an initiative to measure progress toward predicting cell behavior under perturbation. Yusuf earned his Ph.D. at Stanford University, where he was advised by Jure Leskovec and Stephen Quake. Prior to that, he spent four years at GSK as a Machine Learning Engineer working on early-stage drug discovery.

Dr. Yusuf Roohani is a Machine Learning Group Leader at the Arc Institute. His research explores how artificial intelligence can guide experimental design in biological discovery, with a particular focus on predictive models of cell state. Recently, he helped design the Virtual Cell Challenge, an initiative to measure progress toward predicting cell behavior under perturbation. Yusuf earned his Ph.D. at Stanford University, where he was advised by Jure Leskovec and Stephen Quake. Prior to that, he spent four years at GSK as a Machine Learning Engineer working on early-stage drug discovery.

Are you interested in single-cell genomics and AI/ML models? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria.

Conference website: perturb2026.bio

Meet the Speaker: @yusufroohani.bsky.social

5 months ago 1 0 0 0
Dr. Leopold Parts initially trained in mathematics and computer science before switching to molecular biology and genomics for his Ph.D., and high-throughput screening for the postdoctoral research. He is currently a group leader at the Wellcome Sanger Institute, where his team aims to understand human DNA function in its cellular context. To do so, they currently focus on generating data from cell lines whose genomes carry many large-scale systematic changes compared to the reference. His team has created several tools and datasets to probe the editing efficacies of CRISPR/Cas systems, as well as applied them to map the extent of variation in gene phenotypes between individuals.

Dr. Leopold Parts initially trained in mathematics and computer science before switching to molecular biology and genomics for his Ph.D., and high-throughput screening for the postdoctoral research. He is currently a group leader at the Wellcome Sanger Institute, where his team aims to understand human DNA function in its cellular context. To do so, they currently focus on generating data from cell lines whose genomes carry many large-scale systematic changes compared to the reference. His team has created several tools and datasets to probe the editing efficacies of CRISPR/Cas systems, as well as applied them to map the extent of variation in gene phenotypes between individuals.

The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. Don’t forget to register and submit an abstract!

Conference website: perturb2026.bio

Meet the Speaker: @leopoldparts.bsky.social

5 months ago 6 1 0 0
Dr. Thomas Norman is an Assistant Member in the Computational & Systems Biology Program at Memorial Sloan Kettering, where his lab develops and applies Perturb-seq to study and engineer cell state. He co-developed Perturb-seq and has helped expand it into a platform for large-scale functional genomics, including genome-scale screens of all expressed genes, systematic CRISPRa of all human transcription factors, and the development of Multiome Perturb-seq to jointly profile gene expression and chromatin accessibility following perturbation. His lab focuses on fibroblasts as a model of cellular plasticity, with broader goals of understanding how transcriptionally-defined fibroblast subsets are specified, contribute to disease, and can be reprogrammed for therapeutic purposes.

Dr. Thomas Norman is an Assistant Member in the Computational & Systems Biology Program at Memorial Sloan Kettering, where his lab develops and applies Perturb-seq to study and engineer cell state. He co-developed Perturb-seq and has helped expand it into a platform for large-scale functional genomics, including genome-scale screens of all expressed genes, systematic CRISPRa of all human transcription factors, and the development of Multiome Perturb-seq to jointly profile gene expression and chromatin accessibility following perturbation. His lab focuses on fibroblasts as a model of cellular plasticity, with broader goals of understanding how transcriptionally-defined fibroblast subsets are specified, contribute to disease, and can be reprogrammed for therapeutic purposes.

The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. Don’t forget to register and submit an abstract!

Conference website: perturb2026.bio

Meet the Speaker: Thomas Norman

5 months ago 1 0 0 0
Post image

Next week, @mylliabio.bsky.social is heading to the Biotech Summit Austria 2025! Join us in Graz and meet with Thomas Moser and Anke Loregger-Wiesmann to explore CRISPR-based functional genomics!

6 months ago 2 1 0 0
Dr. Xin Jin is an HHMI Freeman Hrabowski Scholar, Associate Professor of Neuroscience at Scripps Research, a member of the Dorris Neuroscience Center, and Adjunct Professor of Cognitive Science at UC San Diego. She received her BSc in Chemistry from MIT and her PhD in Biology from The Rockefeller University working in the Lab of Cori Bargmann. As a Junior Fellow at the Harvard Society of Fellows, she worked with Paola Arlotta, Feng Zhang and Aviv Regev to develop and apply in vivo genetic screening technologies to study brain development and homeostasis. She is the recipient of the Pew Biomedical Scholar, McKnight Scholar Award, Early Career Investigator Award from the International Society of Autism Research and was named as one of the ‘35 Innovators Under 35’ by MIT Tech Review.

Dr. Xin Jin is an HHMI Freeman Hrabowski Scholar, Associate Professor of Neuroscience at Scripps Research, a member of the Dorris Neuroscience Center, and Adjunct Professor of Cognitive Science at UC San Diego. She received her BSc in Chemistry from MIT and her PhD in Biology from The Rockefeller University working in the Lab of Cori Bargmann. As a Junior Fellow at the Harvard Society of Fellows, she worked with Paola Arlotta, Feng Zhang and Aviv Regev to develop and apply in vivo genetic screening technologies to study brain development and homeostasis. She is the recipient of the Pew Biomedical Scholar, McKnight Scholar Award, Early Career Investigator Award from the International Society of Autism Research and was named as one of the ‘35 Innovators Under 35’ by MIT Tech Review.

The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria. Don’t forget to register and submit an abstract!

Conference website: perturb2026.bio
Abstract submission: perturb2026.bio/abstract-sub...

Meet the Speaker: @xinjin.bsky.social

6 months ago 5 1 0 0
Advertisement
Post image

Myllia Biotechnology is heading to @elrig.org Drug Discovery 2025! Meet with Lukas Badertscher, Stefanie Fellinger, and Henrik Schmidt to explore CRISPR-based functional genomics for drug target discovery.

Spotlight Talk, Day 1, 12.40 PM
Posters #3, #45, and #107
Booth D02

6 months ago 3 1 0 0
Dr. Silvia Domcke’s research group at the University of Zurich combines single cell genomics and large-scale CRISPR screens to predict de novo transcription factor activity in mammalian cells and engineer cell state transitions. Previously, Silvia led a computational team at a San Francisco biotech startup, applying in vivo Perturb-Seq for target discovery in complex diseases. A biochemist by training, she became enamored with comparative genomics and perturbation approaches at Memorial Sloan-Kettering Cancer Center in New York, built a foundation in gene regulatory mechanisms during her PhD at the Friedrich Miescher Institute in Basel and expanded this expertise to high-throughput single cell methods during her postdoc at the University of Washington in Seattle.

Dr. Silvia Domcke’s research group at the University of Zurich combines single cell genomics and large-scale CRISPR screens to predict de novo transcription factor activity in mammalian cells and engineer cell state transitions. Previously, Silvia led a computational team at a San Francisco biotech startup, applying in vivo Perturb-Seq for target discovery in complex diseases. A biochemist by training, she became enamored with comparative genomics and perturbation approaches at Memorial Sloan-Kettering Cancer Center in New York, built a foundation in gene regulatory mechanisms during her PhD at the Friedrich Miescher Institute in Basel and expanded this expertise to high-throughput single cell methods during her postdoc at the University of Washington in Seattle.

Don’t forget to register and submit an abstract for the 'High-Content CRISPR Screening' conference, which will take place in Vienna, Austria, on 18–19 March 2026!

Conference website: www.perturb2026.bio

Meet the Speaker: Silvia Domcke

6 months ago 1 0 0 1
Dr. Radu Rapiteanu is a Director of Target Discovery at GSK spearheading target identification and validation strategies across respiratory, kidney, autoimmune, and infectious diseases. He leads global projects and teams at the interface between functional genomics, genetics and single-cell technologies. He specialises in the design and implementation of genetic (CRISPR) and chemogenomic screening campaigns in human primary cells and complex models. Radu holds a Ph.D. from the University of Cambridge. He is a passionate about translating cutting edge technologies into novel therapies.

Dr. Radu Rapiteanu is a Director of Target Discovery at GSK spearheading target identification and validation strategies across respiratory, kidney, autoimmune, and infectious diseases. He leads global projects and teams at the interface between functional genomics, genetics and single-cell technologies. He specialises in the design and implementation of genetic (CRISPR) and chemogenomic screening campaigns in human primary cells and complex models. Radu holds a Ph.D. from the University of Cambridge. He is a passionate about translating cutting edge technologies into novel therapies.

Are you interested in single-cell genomics, multi-modal perturbation data and drug target discovery? We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place from March 18-19, 2026, in Vienna, Austria!

Meet the Speaker: Radu Rapiteanu

www.perturb2026.bio

6 months ago 3 1 0 0
Dr. Mathew Garnett is a Senior Group Leader at the Wellcome Sanger Institute whose research focuses on understanding cancer biology and translating discoveries into new therapies. Early in his career, he helped identify the BRAF cancer gene and revealed key mechanisms regulating cell division and drug responses. His laboratory has pioneered systematic drug and CRISPR screening in cancer models, leading to the identification of treatment biomarkers, new therapeutic targets, and the development of the Cancer Dependency Map. Dr Garnett’s team also established one of the world’s largest biobanks of tumour organoids, contributing extensively to the Human Cancer Model Initiative. A key discovery from his lab identified Werner syndrome helicase as a target in microsatellite unstable cancers, now driving clinical development of WRN inhibitors. Beyond academia, he co-founded Mosaic Therapeutics to advance precision oncology, and his research continues to shape cancer research and drug discovery.

Dr. Mathew Garnett is a Senior Group Leader at the Wellcome Sanger Institute whose research focuses on understanding cancer biology and translating discoveries into new therapies. Early in his career, he helped identify the BRAF cancer gene and revealed key mechanisms regulating cell division and drug responses. His laboratory has pioneered systematic drug and CRISPR screening in cancer models, leading to the identification of treatment biomarkers, new therapeutic targets, and the development of the Cancer Dependency Map. Dr Garnett’s team also established one of the world’s largest biobanks of tumour organoids, contributing extensively to the Human Cancer Model Initiative. A key discovery from his lab identified Werner syndrome helicase as a target in microsatellite unstable cancers, now driving clinical development of WRN inhibitors. Beyond academia, he co-founded Mosaic Therapeutics to advance precision oncology, and his research continues to shape cancer research and drug discovery.

The "High-Content CRISPR Screening" conference will take place on March 18-19, 2026, in Vienna, Austria.

The registration is now open via the conference website:
perturb2026.bio

Meet the Speaker: Mathew Garnett

@mgarnett.bsky.social

6 months ago 3 1 0 0
Prior to co-founding Relation Therapeutics, Dr. Jake Taylor-King was an academic and industry researcher interested in company formation at the intersection of technology, computation, and the clinic. Previously an award-winning mathematician (G-Research prize, Lee Segel Prize), he has degrees from Bristol, Oxford, Cambridge, before later transitioning to biomedicine and genomics at ETH Zürich. Jake’s role as Chief Innovation Officer at Relation cuts across many functions, including leading an experimental technology development group, engaging in ML research, and designing clinical studies for patient tissue access.

Prior to co-founding Relation Therapeutics, Dr. Jake Taylor-King was an academic and industry researcher interested in company formation at the intersection of technology, computation, and the clinic. Previously an award-winning mathematician (G-Research prize, Lee Segel Prize), he has degrees from Bristol, Oxford, Cambridge, before later transitioning to biomedicine and genomics at ETH Zürich. Jake’s role as Chief Innovation Officer at Relation cuts across many functions, including leading an experimental technology development group, engaging in ML research, and designing clinical studies for patient tissue access.

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18–19, 2026, in Vienna, Austria.

The registration is now open via the website:
perturb2026.bio

Meet the Speaker: Jake P. Taylor-King

6 months ago 2 0 0 0
Myllia Biotechnology is looking forward to explore new collaborations in early-stage drug target discovery and CRISPR-based functional genomics: Meet Henrik Schmidt at 📍 BioJapan 2025 in Yokohama, Tokyo from October 8-10 to discuss your next drug discovery partnerships! At Myllia, we perform high-content CRISPR screens in primary human cells, incl. epithelial cells, T cells, dendritic cells and macrophages. Our technology platform enables the systematic identification of genetically validated, high-value targets in autoimmune disease, inflammation and oncology. 📰 Visit www.myllia.com for more information 📩 Contact us via email: info@myllia.com

Myllia Biotechnology is looking forward to explore new collaborations in early-stage drug target discovery and CRISPR-based functional genomics: Meet Henrik Schmidt at 📍 BioJapan 2025 in Yokohama, Tokyo from October 8-10 to discuss your next drug discovery partnerships! At Myllia, we perform high-content CRISPR screens in primary human cells, incl. epithelial cells, T cells, dendritic cells and macrophages. Our technology platform enables the systematic identification of genetically validated, high-value targets in autoimmune disease, inflammation and oncology. 📰 Visit www.myllia.com for more information 📩 Contact us via email: info@myllia.com

Post image

Meet Myllia's @henrik-hs.bsky.social at #BioJapan2025 in Yokohama, Tokyo from October 8-10 to discuss your next CRISPR-based drug target discovery partnerships!

Websites:
myllia.com
myllia.com/events/bio-j...

Contact us via email: info@myllia.com

6 months ago 3 1 0 0
Abstract submissions are now open for the conference on "High-Content CRISPR Screening", taking place in Vienna this March 2026. We invite researchers from across the globe to share their latest work and join the discussion shaping the future of CRISPR screening and genome editing. Scientific themes include * CRISPR-based screening strategies * Perturb-seq and CROP-seq methods * Computational analysis and data interpretation * AI models of human cells * Imaging-based CRISPR screens Date: March 18 & 19, 2026 Location: Vienna, Austria

Abstract submissions are now open for the conference on "High-Content CRISPR Screening", taking place in Vienna this March 2026. We invite researchers from across the globe to share their latest work and join the discussion shaping the future of CRISPR screening and genome editing. Scientific themes include * CRISPR-based screening strategies * Perturb-seq and CROP-seq methods * Computational analysis and data interpretation * AI models of human cells * Imaging-based CRISPR screens Date: March 18 & 19, 2026 Location: Vienna, Austria

High-Content CRISPR Screening Conference

March 18-19, 2026 | Vienna, Austria

Abstract submission is now open! Don’t miss the chance to hear from an outstanding line-up of speakers and connect with leading researchers in the field.

Register now: perturb2026.bio

7 months ago 2 0 0 0
Dr. Wei Li is currently an associate professor at the University of Maryland School of Medicine (UMSOM) and the University of Maryland-Institute for Health Computing (UM-IHC). His laboratory uses novel computational, AI/ML and genome engineering approaches to understand the functions of the mammalian genome, especially in the context of human physiology and disease. His laboratory developed several widely used algorithms for genome editing, RNA sequencing, functional genomics screening, and Perturb-seq/CROP-seq. Collaborating with many scientists around the world, his laboratory developed models to design new gene editing systems with high efficiency and specificity, applied novel AI/ML approaches in various types of biological and biomedical data, and identified clinically relevant hits and synergistic targets in critical human diseases including breast/prostate cancer, brain tumor and infectious diseases.

Dr. Wei Li is currently an associate professor at the University of Maryland School of Medicine (UMSOM) and the University of Maryland-Institute for Health Computing (UM-IHC). His laboratory uses novel computational, AI/ML and genome engineering approaches to understand the functions of the mammalian genome, especially in the context of human physiology and disease. His laboratory developed several widely used algorithms for genome editing, RNA sequencing, functional genomics screening, and Perturb-seq/CROP-seq. Collaborating with many scientists around the world, his laboratory developed models to design new gene editing systems with high efficiency and specificity, applied novel AI/ML approaches in various types of biological and biomedical data, and identified clinically relevant hits and synergistic targets in critical human diseases including breast/prostate cancer, brain tumor and infectious diseases.

The registration and abstract submission is now open for the "High-Content CRISPR Screening" conference on March 18–19, 2026, in Vienna, Austria!

Conference website:
www.perturb2026.bio

Abstract submission:
www.perturb2026.bio/abstract-sub...

Meet the Speaker: Wei Li

7 months ago 4 0 0 0
Advertisement
Dr. Francesco Iorio is a Research Group Leader at Human Technopole in Milan, where he leads a Computational Pharmacogenomics and Functional Genomics Laboratory. His research focuses on characterising cancer vulnerabilities and synthetic lethalities through large-scale CRISPR screening and exploiting them for early anti-cancer drug discovery. He is the recipient of a European Research Council (ERC) Consolidator Grant focused on developing predictive tools for personalised oncology. Francesco has contributed to foundational tools and resources for CRISPR-data processing, interpretation and use for therapeutic target prioritisation, and has led efforts to develop computational methods for drug repurposing and precision oncology. Prior to joining Human Technopole, he worked at the Wellcome Sanger Institute and EMBL-EBI in Cambridge, UK. He is passionate about the intersection of artificial intelligence and biomedical research and about building collaborative, interdisciplinary communities in functional genomics.

Dr. Francesco Iorio is a Research Group Leader at Human Technopole in Milan, where he leads a Computational Pharmacogenomics and Functional Genomics Laboratory. His research focuses on characterising cancer vulnerabilities and synthetic lethalities through large-scale CRISPR screening and exploiting them for early anti-cancer drug discovery. He is the recipient of a European Research Council (ERC) Consolidator Grant focused on developing predictive tools for personalised oncology. Francesco has contributed to foundational tools and resources for CRISPR-data processing, interpretation and use for therapeutic target prioritisation, and has led efforts to develop computational methods for drug repurposing and precision oncology. Prior to joining Human Technopole, he worked at the Wellcome Sanger Institute and EMBL-EBI in Cambridge, UK. He is passionate about the intersection of artificial intelligence and biomedical research and about building collaborative, interdisciplinary communities in functional genomics.

The registration and abstract submission for the "High-Content CRISPR Screening" conference on March 18–19, 2026, in Vienna, Austria is now open!

Conference website: lnkd.in/d8KACZy5
Abstract submission: lnkd.in/dcyuwXNM

Meet the Speaker: Francesco Iorio

@francescoiorio.bsky.social

7 months ago 1 0 0 0
Dr. Luke Gilbert is a Professor at the University of California, San Francisco and a Core Investigator at the Arc Institute. Dr. Gilbert was an early pioneer in repurposed CRISPR systems that are used to turn genes on (CRISPRa) and off (CRISPRi). More recently, the Gilbert lab has developed new strategies for editing heritable epigenetic memories (CRISPRoff/on) and for systematically mapping human genetic interactions at very large scales or at single cell resolution. Medically, the Gilbert lab is focusing on using CRISPR functional genomics expertise to tackle big problems in cancer biology.

Dr. Luke Gilbert is a Professor at the University of California, San Francisco and a Core Investigator at the Arc Institute. Dr. Gilbert was an early pioneer in repurposed CRISPR systems that are used to turn genes on (CRISPRa) and off (CRISPRi). More recently, the Gilbert lab has developed new strategies for editing heritable epigenetic memories (CRISPRoff/on) and for systematically mapping human genetic interactions at very large scales or at single cell resolution. Medically, the Gilbert lab is focusing on using CRISPR functional genomics expertise to tackle big problems in cancer biology.

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18–19, 2026, in Vienna, Austria.

The registration is now open via the conference website:
lnkd.in/d8KACZy5

Meet the Speaker: Luke Gilbert

7 months ago 2 2 0 0
Dr. Christoph Bock is a Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and Professor of Medical Informatics at the Medical University of Vienna. His research combines experimental biology (single-cell sequencing, epigenetics, CRISPR screening, synthetic biology) with computational methods (bioinformatics, machine learning, artificial intelligence) – for cancer, immunology, and precision medicine (https://www.bocklab.org & https://bsky.app/profile/bocklab.bsky.social).

Dr. Christoph Bock is a Principal Investigator at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences and Professor of Medical Informatics at the Medical University of Vienna. His research combines experimental biology (single-cell sequencing, epigenetics, CRISPR screening, synthetic biology) with computational methods (bioinformatics, machine learning, artificial intelligence) – for cancer, immunology, and precision medicine (https://www.bocklab.org & https://bsky.app/profile/bocklab.bsky.social).

We’re thrilled to announce that the "High-Content CRISPR Screening" conference will take place on March 18–19, 2026, in Vienna, Austria.

The registration is now open via the conference website:
lnkd.in/d8KACZy5

Meet the Speaker: Christoph Bock

@bocklab.bsky.social

7 months ago 6 3 0 0
Meet Myllia at: 📍 BIO Japan 2025 - Tokyo, 8-10 October 📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October 📍 BIO Europe 2025 - Vienna, 3-5 November

Meet Myllia at: 📍 BIO Japan 2025 - Tokyo, 8-10 October 📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October 📍 BIO Europe 2025 - Vienna, 3-5 November

Exciting times ahead for @mylliabio.bsky.social in Q4 2025

📍 BIO Japan 2025 - Tokyo, 8-10 October
📍 ELRIG Drug Discovery 2025 - Liverpool, 21-22 October
📍 BIO Europe 2025 - Vienna, 3-5 November

📰 Website: www.myllia.com
📩 Contact: info@myllia.com

7 months ago 2 1 0 0
At Myllia, our mission is to accelerate drug discovery through high-content CRISPR screening. Since our founding in 2018 by Thomas Moser (CEO), Tilmann Buerckstuemmer (CSO), and Christoph Bock (Scientific Advisor), we have partnered with biotech and pharmaceutical companies globally to support their drug discovery programmes.

At Myllia, our mission is to accelerate drug discovery through high-content CRISPR screening. Since our founding in 2018 by Thomas Moser (CEO), Tilmann Buerckstuemmer (CSO), and Christoph Bock (Scientific Advisor), we have partnered with biotech and pharmaceutical companies globally to support their drug discovery programmes.

We are committed to identifying and validating drug targets through CRISPR screening in the most biologically relevant cellular models:   - 150+ CRISPR screens in cell lines and primary human cells - 35+ collaborative projects worldwide - End-to-end workflows from experimental screening to computational analysis

We are committed to identifying and validating drug targets through CRISPR screening in the most biologically relevant cellular models:   - 150+ CRISPR screens in cell lines and primary human cells - 35+ collaborative projects worldwide - End-to-end workflows from experimental screening to computational analysis

Our platform integrates multiple CRISPR modalities with primary human cell types, combined with high-content readouts such as single-cell RNA-Seq, CITE-Seq, FACS, and fitness assays. 👇 Are you curious how functional genomics can transform drug discovery? Follow us for updates & insights, and check out www.myllia.com

Our platform integrates multiple CRISPR modalities with primary human cell types, combined with high-content readouts such as single-cell RNA-Seq, CITE-Seq, FACS, and fitness assays. 👇 Are you curious how functional genomics can transform drug discovery? Follow us for updates & insights, and check out www.myllia.com

🧬 Meet #TeamMyllia

Our mission is to accelerate drug discovery through high-content CRISPR screening:

- 150+ CRISPR screens in cell lines and primary cells
- 35+ collaborative projects worldwide
- End-to-end workflows from screening to bioinformatics

www.myllia.com

8 months ago 4 2 0 0
Post image

📢 @mylliabio.bsky.social is heading to #IUIS2025 - we’re excited to share that Anke Loregger, Myllia’s Director of R&D, will attend the International Congress of Immunology (IUIS) 2025 in Vienna! Interested in the VISTA platform?

Poster: II.265 on Wednesday, August 20 at 12.15 PM

www.myllia.com

8 months ago 3 2 0 0
Post image

🗓️ @mylliabio.bsky.social sponsors the first conference on "High-Content CRISPR Screening" from March 18-19, 2026 in Vienna: perturb2026.bio

Scientific topics:
🔬 CRISPR-based screening strategies
🧬 Perturb-Seq & CROP-Seq
💻 Computational analyses
💻 AI models of human cells
📸 Image-based screens

8 months ago 5 6 0 0
Advertisement
Post image

🧬 Unlocking target discovery in primary human dendritic cells with VISTA™

At @mylliabio.bsky.social, we’re enabling functional genomics in primary immune cells. Our VISTA™ platform combines pooled CRISPRi with scRNA-Seq to systematically map gene function at scale!

Contact us via: info@myllia.com

8 months ago 3 2 0 0